Gang Lu

List of Publications by Year
in descending order

13 papers	2,683 citations	759233 12 h-index	1125743 13 g-index
14 all docs	14 docs citations	14 times ranked	3753 citing authors

#	Article	IF	Citations
1	The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. Science, 2014, 343, 305-309.	12.6	1,196
2	A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. Nature, 2016, 535, 252-257.	27.8	414
3	SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nature Chemical Biology, 2018, 14, 981-987.	8.0	210
4	A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. Journal of Medicinal Chemistry, 2018, 61, 535-542.	6.4	188
5	CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood, 2015, 126, 779-789.	1.4	148
6	Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes and Development, 2014, 28, 1429-1444.	5.9	111
7	CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood, 2021, 137, 661-677.	1.4	103
8	Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. Nature Communications, 2017, 8, 14922.	12.8	80
9	Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor. Cancer Cell, 2014, 26, 222-234.	16.8	71
10	CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2021, 64, 1835-1843.	6.4	63
11	UBE2G1 governs the destruction of cereblon neomorphic substrates. ELife, 2018, 7, .	6.0	61
12	Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4. Scientific Reports, 2020, 10, 2864.	3.3	24
13	Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen. Blood Advances, 2021, 5, 2027-2039.	5.2	14